Engineered immune cells take on rare solid tumors in first human trial
NCT ID NCT07297667
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 6 times
Summary
This early-phase study tests a new treatment called GCAR1, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells carrying a specific marker (GPNMB). The study enrolls 30 adults in Canada with advanced alveolar soft part sarcoma, renal cell carcinoma, or triple-negative breast cancer that has not responded to other treatments. The main goals are to find a safe dose and see if the therapy can shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALVEOLAR SOFT PART SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arthur J.E. Child Comprehensive Cancer Centre
RECRUITINGCalgary, Alberta, T2N 5G2, Canada
-
University Health Network
RECRUITINGToronto, Ontario, M5G 2M9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Can a Two-Pronged antibody boost Chemo's power against a tough breast cancer?
- Can a new drug rally the immune system against Hard-to-Treat cancers?